KHL Foundation opens gene therapy medical tourism for patients over 60

The KHL Foundation, established by Kenneth Scott (b. 1942) and Helga Sands (b. 1938), has launched a medical tourism program that makes three carefully selected gene therapies available to adults over 60: klotho, follistatin, and sirtuin 1. Each targets core aging mechanisms—vascular inflammation, muscle regeneration, and mitochondrial function—aiming to restore youthful performance and resilience over 15 to 20 years. The treatment combines same-day intramuscular follistatin injections with intranasal klotho and sirtuin 1 administration under local anesthetic. This initiative exemplifies a broader market shift: while companies like Bioviva, Triple Helix, and Unlimited Bio continue development, certain patients pursue medical tourism to circumvent US and European regulatory timelines. For the longevity-conscious reader who values patient autonomy and resists a decade-long wait for conventional approval, this represents a genuine frontier—though published outcome data remain sparse, making clinic-quality differentiation difficult.